The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

Chronic pain is a global health challenge, with current treatment options often limited by side effects, addiction risk, and diminished effectiveness over time. In a new study, Yale researchers ...

Nerve injury or dysfunction in the peripheral and central nervous systems are the ... prerequisite for the rational development of novel analgesic drugs for the therapy of neuropathic pain.

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

The FDA approves Journavx, the first new non-opioid pain medication in over 20 years, offering a safer alternative for ...

“A new non-opioid analgesic therapeutic ... NaV1.8 pain signal in the peripheral nervous system. This channel is not expressed in the brain or anywhere else in the central nervous system ...

DELRAY BEACH, FL / ACCESS Newswire / January 29, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal ...